In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Jeff Draa, Board of Directors, Tech Coast Angels
- Gabor Garai, Partner, Foley & Lardner
- Vanessa Herbert, Senior Manager, PricewaterhouseCoopers
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- Robert Mashal, M.D., President & CEO, NKT Therapeutics
- David Parrot, M.B.A., Managing Director, BMO Capital Markets Corp.
Related Insights
21 April 2025
Health Care Law Today
Prescription Drugs: Executive Order Aims to Lower Prices
On April 15, 2025, President Trump signed an executive order (EO) with the aim of reducing the cost of prescription drugs.
21 April 2025
Health Care Law Today
MedTech Round Table: What the Trump Administration Means for Companies and Investors
Foley & Lardner LLP hosted and participated in a MedTech round table of investors and business leaders, including chief executive officers, partners, directors, innovation leads, investment funds managers and partners, and general counsels. There was collective interest in understanding how these MedTech leaders are adjusting to the changing business and regulatory environment under the second Trump administration.
21 April 2025
Labor & Employment Law Perspectives
Supreme Court’s E.M.D. Sales v. Carrera Decision: A Victory for Employers Navigating FLSA Exemptions
In the case at issue, E.M.D. Sales, Inc. v. Carrera, the court clarified the applicable standard of proof, ruling that employers need only demonstrate by a "preponderance of the evidence," the standard used in most civil cases, that an employee qualifies for an FLSA exemption, rather than the higher more stringent "clear and convincing evidence" standard previously applied by the Fourth Circuit Court of Appeals.